Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus

12 January 2021: Original Paper

Shun Nishioka ^ABCDE , Takeshi Ishimura ^ACDE* , Takahito Endo ^B , Naoki Yokoyama ^BC , Satoshi Ogawa ^BCD , Masato Fujisawa ^E

DOI: 10.12659/AOT.926476

Ann Transplant 2021; 26:e926476

Table 2 Univariate and multivariate analysis of the parameters predicting the progression of the graft fibrosis (ΔFI >10%).

	Univariate analysis	Multivariate analysis
	P value	Odds ratio	95% CI	P value
EVR early add-on (yes no)		0.036	0.0029–0.44
Recipient age, years (≤50 >50)	0.20
Donor age, years (≤50 >50)	0.34
Donor type (living-related deceased)	0.078
CIT, minutes (≤100 >100)	0.035	0.36	0.054–2.4	0.29
BMI (≤25 >25)	0.88
Pre-KTx dialysis period, days(≤1000 >1000)	0.014	0.25	0.060–1.0	0.052
HLA mismatch(0–3 4–6)	0.60
DM (− +)	0.28
HT (≤sBP 140 mmHg >140 mmHg)	0.16
LDL-chol (≤140 mg/dl >140 mg/dl)	0.49
Triglyceride (≤150 mg/dl >150 mg/dl)	0.41
eGFR at 3months after KTx, ml/min/1.73 m (≤60 >60)	0.44
Tac C at 1year after KTx, ng/ml (≤5 >5)	0.011	0.33	0.065–1.7	0.26
Tac C at 3year after KTx, ng/ml (≤5 >5)	0.11
ΔFI=FI at 3 years after KTx–FI at 3 months after KTx; FI – fibrosis index; EVR – everolimus; CIT – cold ischemic time; BMI – body mass index; KTx – kidney transplantation; HLA – human leukocyte antigen; DM – diabetes mellitus; HT – hypertension; sBP – systolic blood pressure; LDL – low density lipoprotein; eGFR – estimated glomerular filtration rate; Tac – tacrolimus; C – trough concentration.